Home
This site is intended for healthcare professionals

ARIA Clinical Snapshot Series: Re-Initiating Therapy After ARIA Resolution

CME Material and Disclosures

This program is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally. Excluding the United Kingdom.

Who Should Participate

This program is designed for healthcare professionals involved in Alzheimer’s disease diagnosis, imaging, treatment, and acute evaluation.

Faculty

Dr. Anton Porsteinsson

Anton Porsteinsson, MD, is the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program (AD-CARE) and the William B. and Sheila Konar Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry. Board-certified in Psychiatry with specialized qualifications in Geriatric Psychiatry, he is an internationally recognized authority on Alzheimer's disease, dementia, and memory disorders. Dr. Porsteinsson's distinguished career focuses on clinical trials, biomarkers, neuroimaging, and novel pharmacologic therapies aimed at addressing both cognitive loss and behavioral disturbances. As a leading investigator for prominent national prevention and treatment trials and the author of hundreds of research publications, he brings profound expertise to this session on navigating complex treatment decisions and coordinating multidisciplinary care across the patient pathway.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Anton Porsteinsson has the following relevant financial relationships: Consultant: Acadia; Alzheon; Axsome; Beren Therapeutics; Biogen; BMS; Cognition Therapeutics; Cognito; Eli Lilly; MapLight Therapeutics; Neumora; Novartis; ONO Pharmaceuticals; Otsuka; Voyager; Xenon. Advisor: Acadia; Axsome; Beren Therapeutics; Biogen; Eli Lilly. Speaker: Acadia; Axsome; Beren Therapeutics; Biogen; Eli Lilly. Researcher: Eisai; Eli Lilly; Roche.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

jointly accredited.webp

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

aapa_Cat1_CME-412x398.png

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting November 13th 2026, and will expire on August 4th 2027.

Estimated time to complete this activity: 15 minutes.